Pharmalittle: We’re reading about Moderna’s $2.25 billion settlement, FDA warning letters, and more
Moderna settled a patent dispute with Roivant for up to $2.25 billion, and Virginia is considering a prescription drug affordability board.Summary
This Pharmalittle update covers two key developments in the pharmaceutical industry. First, Moderna has agreed to pay Roivant up to $2.25 billion to settle patent infringement claims related to its Covid-19 vaccine. Roivant will initially receive $950 million, with an additional $1.3 billion contingent on the outcome of Moderna’s appeal to offload liability to the federal government. This settlement, occurring just before a scheduled jury trial, represents a significant financial gain for Roivant and avoids a potentially unfavorable outcome for Moderna, which is currently facing financial constraints. Second, Virginia lawmakers are advancing a plan to establish a prescription drug affordability board that will leverage Medicare’s price negotiations as a benchmark. This approach aims to identify and regulate the prices of drugs already targeted by Medicare, setting upper payment limits to control costs, and potentially surpassing the efforts of other states with similar boards.
(Source：Stat)